Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
Amid unprecedented challenges to routine healthcare access, trial results mark a first for a critically needed HIV prevention measure An investigational drug administered by injection every […]
In the six weeks before South Africa responded its first diagnoses of COVID-19 with the start of physical distancing measures, more than 47,000 people on average […]
What we have learned from HIV can guide responses to COVID-19 that are innovative, effective and inclusive, and can help end the pandemic faster The following […]
The following is a guest post by Kenneth G. Castro, MD, FIDSA Since its formation in 1948, WHO has relied heavily on the U.S. for collaborations […]